Rapport Therapeutics, Inc. (RAPP) Fair Value 2026

RAPP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-28, Rapport Therapeutics, Inc. (RAPP) trades at $48.77. QOC: 4.8/10. Value Trap Risk: 32/100 (LOW). 0/13 models active.

Key Facts

Ticker
RAPP
Price
$48.77
Quality Score
4.8/10
Value Trap Risk
32/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.8/10 signals weak fundamentals

What Fair Value Does Each Model Give RAPP?

0 Intrinsic Value Models vs. Current Price ($48.77)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Rapport Therapeutics, Inc. (RAPP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Rapport Therapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About RAPP?

0 of 13 models are currently active for RAPP. See which stocks rank higher →

How Does RAPP Rank in Biotechnology?

Among 625 Biotechnology stocks, RAPP ranks #362 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Rapport Therapeutics, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating RAPP should weigh these sector-specific dynamics alongside our model-derived fair values.

Is RAPP a Value Trap?

CirclFi's Value Trap algorithm assigns RAPP a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Rapport Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Rapport Therapeutics, Inc.'s fundamental quality profile registers 4.8/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RAPP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Rapport Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

KTTAPasithea Therapeutics Corp.QOC 4.8APREAprea Therapeutics, Inc.QOC 4.8REPLReplimune Group, Inc.QOC 4.8DMRADamora Therapeutics, Inc.QOC 4.8MPLTMapLight Therapeutics, Inc.QOC 4.8NNVCNanoViricides, Inc.QOC 4.8GTBPGT Biopharma, Inc.QOC 4.1PRTAProthena Corporation plcQOC 7.0IVVDInvivyd, Inc.QOC 5.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: KTTA · APRE · REPL · DMRA · MPLT · NNVC · GTBP · PRTA · IVVD · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to RAPP?

5 companies across all industries closest to RAPP’s Quality of Company score of 4.8/10.

MFONMobivity Holdings Corp.QOC 4.8INIOInnio N.V.QOC 4.8FJETStarfighters Space, Inc.QOC 4.8BMGLBasel Medical Group LtdQOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MFON · INIO · FJET · BMGL · NVDA

Where Does RAPP Sit in CirclFi's Biotechnology Rankings?

RAPP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Rapport Therapeutics, Inc.’s Valuation?

What is Rapport Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Rapport Therapeutics, Inc. (RAPP). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RAPP overvalued or undervalued right now?

At $48.77, 0 of 0 active models suggest RAPP may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Rapport Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.8 mean for RAPP?

Rapport Therapeutics, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RAPP?

CirclFi analyzes RAPP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is RAPP a value trap in 2026?

Rapport Therapeutics, Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Rapport Therapeutics, Inc. (RAPP) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/RAPP/ · Methodology
Primary sources for this RAPP valuation
  • Financial statements: Rapport Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0002012593) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RAPP as of ; valuations recomputed .